Insulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024.
- Revenue
- +19.2%
- EPS
- +64.1%
- Free cash flow
- −29.8%
- Total debt
- −5.19%
Quarter to September 2026, against a year earlier
Follow PODD
Alert me
Insulet Corporation (PODD) Current ratio
Insulet Corporation's current ratio at the end of the quarter to 30 September 2026 was 2.5×, down 0.3× from fiscal 2025 (2.8×). Over the past ten years it has ranged from 2.8× (fiscal 2025) to 6.6× (fiscal 2016) — the current reading is the lowest in ten years. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 2.8× | (21.37%) |
| FY2024 | 3.6× | 2.03% |
| FY2023 | 3.5× | (2.63%) |
| FY2022 | 3.6× | (38.01%) |
| FY2021 | 5.8× | (3.28%) |
| FY2020 | 6.0× | 60.35% |
| FY2019 | 3.7× | (6.00%) |
| FY2018 | 4.0× | (36.15%) |
| FY2017 | 6.2× | (5.99%) |
| FY2016 | 6.6× | 126.87% |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 2.5× | 0.89% |
| Jun 2026 | 2.5× | (0.07%) |
| Mar 2026 | 2.5× | (11.65%) |
| Dec 2025 | 2.8× | (1.97%) |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| PEN Penumbra, Inc. compare | 5.9× |
| TXG 10x Genomics compare | 5.7× |
| GKOS Glaukos Corporation compare | 4.6× |
| GMED Globus Medical, Inc. compare | 4.3× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 3.2× |
| BIO Bio-Rad Laboratories, Inc. compare | 3.2× |
| PODD Insulet Corporation | 2.5× |
| SNN Smith & Nephew SNATS, Inc. compare | 2.1× |
| BRKR Bruker Corporation compare | 1.8× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on PODD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement